Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.52 |
| ▸ | HTR2B | P41595 | 3/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31283854 | 0.88 | HTR2A (0.54) | HTR2AHTR2BHTR2CTHRBMAPT | |
| SCHEMBL2218373 | 0.88 | HTR2A (0.54) | HTR2AHTR2BHTR2CTHRBMAPT | |
| SCHEMBL30589450 | 0.86 | HTR2A (0.55) | HTR2AHTR2BHTR2CTHRBMAPT | |
| SCHEMBL6714650 | 0.86 | HTR2A (0.55) | HTR2AHTR2BHTR2CTHRBMAPT | |
| SCHEMBL11668591 | 0.84 | PPARG (0.48) | THRBMAPTCYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL23125015 | 0.84 | HTR2A (0.52) | HTR2AHTR2BHTR2CTHRBMAPT | |
| SCHEMBL20543990 | 0.84 | HTR2A (0.60) | HTR2AHTR2BHTR2CTHRBMAPT | |
| SCHEMBL3981772 | 0.83 | HTR2A (0.58) | HTR2AHTR2BHTR2CMAPTADRA2C | |
| SCHEMBL4436742 | 0.83 | HTR2A (0.51) | HTR2AHTR2BHTR2CTHRBMAPT | |
| SCHEMBL16571756 | 0.82 | HTR2A (0.50) | HTR2AHTR2BHTR2CTHRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156644-A1 | Use of thiazole derivatives and analogues in the treatment of cancer | BETAGENON AB (SE) | 2009-06-18 | — | — | US | disclosed |
| US-20090136472-A1 | Use of thiazole derivatives and analogues in disorders caused by free fatty acids | BETAGENON AB (SE) | 2009-05-28 | — | — | US | disclosed |
| CN-101277692-A | Use of thiazole derivatives and analogues in the treatment of cancer | BETAGENON AB (SE) | 2008-10-01 | — | — | CN | disclosed |
| CN-101237866-A | Use of thiazole derivatives and analogues in the treatment of cancer | BETAGENON AB (SE) | 2008-08-06 | — | — | CN | disclosed |
| WO-2008065409-A2 | COMBINATION FOR USE IN THE TREATMENT OF CANCER, COMPRISING TAMOXIFEN OR AN AROMATASE INHIBITOR | BETAGENON AB (SE) | 2008-06-05 | — | — | WO | disclosed |
| EP-1906955-A2 | USE OF THIAZOLE DERIVATIVES AND ANALOGUES IN THE TREATMENT OF CANCER | Betagenon AB (SE) | 2008-04-09 | — | — | EP | disclosed |
| EP-1906956-A2 | USE OF THIAZOLE DERIVATIVES AND ANALOGUES IN DISORDERS CAUSED BY FREE FATTY ACIDS | Betagenon AB (SE) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007010281-A2 | USE OF THIAZOLE DERIVATIVES AND ANALOGUES IN DISORDERS CAUSED BY FREE FATTY ACIDS | BETAGENON AB (SE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007010273-A2 | USE OF THIAZOLE DERIVATIVES AND ANALOGUES IN THE TREATMENT OF CANCER | BETAGENON AB (SE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156644-A1 | Use of thiazole derivatives and analogues in the treatment of cancer | TBXA2R, TSHR, FOLR1 | HTR2A 446/4885HTR2B 1324/4885HTR2C 1019/4885 |
| US-20090136472-A1 | Use of thiazole derivatives and analogues in disorders caused by free fatty acids | FFAR2, FFAR1, FFAR4 | HTR2A 166/4885HTR2B 803/4885HTR2C 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.